POLARITYTE INC (PTE) Stock Price, Forecast & Analysis
USA - NASDAQ:PTE - US7310942070 - Common Stock
PTE Key Statistics, Chart & Performance
The current stock price of PTE is 0.241 USD. In the past month the price decreased by -36.91%. In the past year, price decreased by -85.39%.
PTE Latest News, Press Relases and Analysis
PTE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.44B | ||
| AMGN | AMGEN INC | 15.3 | 180.19B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 109.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.85 | 70.86B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.19 | 59.11B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.65B | ||
| BIIB | BIOGEN INC | 9.43 | 23.15B | ||
| INCY | INCYTE CORP | 16.81 | 21.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.33 | 20.68B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.37 | 14.66B |
Related stock screener links
About PTE
Company Profile
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
Company Info
POLARITYTE INC
1960 S. 4250 West
Salt Lake City UTAH 84116 US
CEO: David Seaburg
Employees: 42
Phone: 13852663151.0
POLARITYTE INC / PTE FAQ
What does PTE do?
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The company is headquartered in Salt Lake City, Utah and currently employs 42 full-time employees. Its first regenerative tissue product is SkinTE. Its SkinTE is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm's development projects include SkinTE Point-of-Care Device, SkinTE Cryo and Other Tissue Regeneration Products. SkinTE Cryo allows it to offer multiple deployments from one original harvest through a cryopreservation process. The core technology of SkinTE is minimally polarized functional units (MPFUs). MPFUs are multi-cellular segments created from a piece of the patient’s healthy skin.
What is the stock price of POLARITYTE INC today?
The current stock price of PTE is 0.241 USD. The price decreased by -0.82% in the last trading session.
Does POLARITYTE INC pay dividends?
PTE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PTE stock?
PTE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is PTE stock listed?
PTE stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for PTE stock?
POLARITYTE INC (PTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.41).
Would investing in POLARITYTE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PTE.
PTE Technical Analysis
PTE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PTE. Both the profitability and financial health of PTE have multiple concerns.
PTE Financial Highlights
Over the last trailing twelve months PTE reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 61.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PTE Forecast & Estimates
5 analysts have analysed PTE and the average price target is 0.82 USD. This implies a price increase of 238.59% is expected in the next year compared to the current price of 0.241.
For the next year, analysts expect an EPS growth of 48.01% and a revenue growth -100% for PTE